Roth Capital remains a buyer of TG Therapeutics after GENUINE announcement
After TG Therapeutics announced that it amended the Phase 3 GENUINE study to have overall response rate as the primary endpoint, Roth Capital analyst Joseph Pantginis says the company is making the hard but right decision. While perceptions are negative on trial amendments, the analyst believes this clarity on timelines, the robustness of Phase 2 data and important drug approval precedents continue to point to a positive outcome for the study. Pantginis believes TG Therapeutics' shares are being oversold, and reiterates a Buy rating and $33 price target on the stock. In late morning trading, shares of TG Therapeutics have dropped more than 14% to $7.07.